Summary & Overview

HCPCS M1228: HCV Treatment Initiation Within 3 Months of Reactive Antibody Test

HCPCS Level II code M1228 documents initiation of hepatitis C virus (HCV) treatment within three months for patients with a reactive HCV antibody and confirmed HCV viremia. The code captures a critical window for linkage to care and treatment start, reflecting efforts to reduce HCV-related morbidity, prevent transmission, and align clinical workflows with quality measures. Nationally, timely HCV treatment initiation is a key public health and payer priority as direct-acting antiviral therapies yield high cure rates when started promptly after diagnosis.

Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find context on clinical intent and service settings, typical sites of care where the service is delivered, and the types of benchmarks and policy considerations that inform coverage and quality measurement for HCV treatment initiation. The publication outlines how M1228 functions as a tracking and reporting code for timely treatment starts, summarizes its relevance to population health and payer programs, and highlights where input data is not available. Data not available in the input will be noted explicitly where applicable.

AetnaBlue Cross Blue ShieldCigna HealthUnitedHealthcareMedicareM1228HCPCS Level IIhepatitis CHCV treatmenttreatment initiationviral testingquality measureoutpatient care

Billing Code Overview

HCPCS Level II code M1228 describes a measure of timely initiation of hepatitis C virus (HCV) treatment: a patient with a reactive HCV antibody test who has a follow-up HCV viral test detecting viremia and has HCV treatment initiated within 3 months of the reactive HCV antibody test.

Service type: HCV treatment initiation following confirmed viremia.

Typical site of service: Outpatient clinics, infectious disease or hepatology specialty clinics, primary care settings, and community health centers where HCV testing and treatment initiation occur.

Data not available in the input.

Clinical & Coding Specifications

Clinical Context

A 46-year-old patient presents to a primary care clinic for routine bloodwork and is found to have a reactive hepatitis C virus (HCV) antibody test (reactive HCV Ab). The clinic orders a confirmatory quantitative HCV RNA PCR. The follow-up HCV viral test detects HCV viremia, confirming active infection. Within three months of the reactive antibody test, the patient is evaluated in a hepatology or infectious disease clinic, receives baseline staging (including liver function tests, HCV genotype if indicated, and fibrosis assessment via transient elastography or serum fibrosis markers), and is started on direct-acting antiviral therapy (DAA) with a documented treatment start date. Typical workflow steps include: ordering confirmatory HCV RNA, clinical evaluation for treatment readiness and contraindications, baseline laboratory and imaging as indicated, medication authorization and patient education, and initiation of antiviral therapy. Typical site of service is outpatient clinic (primary care, hepatology, infectious disease) or ambulatory infusion/pharmacy setting if medication administration or specialty pharmacy coordination is required. Typical patient scenario: adult with newly diagnosed chronic HCV after screening, insured by commercial or government payors, with treatment initiation documented within 3 months of the reactive antibody screening test.

Coding Specifications

Modifier	Description	When to Use
`22`	Increased procedural services	Use when services require substantially greater work than normally required (document justification).
`23`	Unusual anesthesia	Use if an unusual circumstance requires general anesthesia for a procedure that normally does not require it.
`52`	Reduced services	Use when service is partially reduced or discontinued.
`53`	Discontinued procedure	Use when procedure started but discontinued due to extenuating circumstances.
`54`	Surgical care only	Use when multiple providers share components and one performs only the surgical care.
`55`	Postoperative management only	Use when provider performs only postoperative care.
`56`	Preoperative management only	Use when provider performs only preoperative care.
`62`	Two surgeons	Use when two surgeons work together as primary surgeons.
`AS`	Physician assistant, nurse practitioner, or clinical nurse specialist services for assistant at surgery	Use when an assistant-at-surgery is a PA/NP/CNS and the payor recognizes the modifier.
`CQ`	Service furnished by a provider in a federally qualified health center (FQHC) billing under specific waivers	Use when applicable to site-specific billing rules.

Taxonomy Code	Specialty	Notes
`207RH0000X`	Infectious Disease	Specialists who evaluate and initiate HCV antiviral therapy.
`207RC0000X`	Gastroenterology	Hepatology services often coded under gastroenterology taxonomy for liver disease management.
`207Q00000X`	Family Medicine	Primary care clinicians who screen, confirm, and initiate or refer for HCV treatment.
`208D00000X`	Internal Medicine	Hospital- or clinic-based internists managing HCV diagnosis and treatment initiation.
`363L00000X`	Clinical Pharmacy	Clinical pharmacists involved in medication management, prior authorization, and patient education.

Related Diagnoses

ICD-10 Code	Description	Clinical Relevance
`B18.2`	Chronic viral hepatitis C	Primary diagnosis for patients with confirmed HCV viremia and indication for antiviral treatment.
`B19.20`	Unspecified viral hepatitis C without hepatic coma	Used when diagnosis is hepatitis C without specification of acute vs chronic in some documentation contexts.
`Z11.59`	Encounter for screening for other viral diseases (includes HCV screening)	Represents the screening encounter when a reactive HCV antibody is identified.
`Z20.9`	Contact with and (suspected) exposure to communicable disease, unspecified	May be used when documenting exposure history prompting HCV testing.
`R74.0`	Nonspecific elevation of levels of transaminase and lactic acid dehydrogenase	Documented abnormal liver enzymes that often accompany evaluation prior to treatment initiation.

Related CPT Codes

CPT Code	Description	Relationship to This Procedure
`36415`	Collection of venous blood by venipuncture	Often performed to obtain specimens for HCV antibody and HCV RNA testing prior to treatment initiation.
`87521`	Infectious agent detection by nucleic acid (DNA or RNA); hepatitis C virus, amplified probe technique	Represents the HCV RNA qualitative or quantitative PCR test used to confirm viremia.
`87491`	Infectious agent detection by nucleic acid (DNA or RNA); hepatitis C, single probe, real-time (e.g., HCV RNA)	Commonly used for HCV RNA testing in clinical workflows.
`77085`	Transient elastography (FibroScan)	Noninvasive assessment of liver fibrosis often performed before initiating HCV therapy.
`99406`	Tobacco use cessation counseling, intermediate, greater than 3 minutes up to 10 minutes	Counseling services that may be provided during an HCV treatment visit as part of preventive care and risk modification.